article thumbnail

Building A Telemedicine Company – Challenges and Best Practices

HIT Consultant

However, the industry’s growth rate experienced a remarkable surge, and the market size is now projected to reach a whopping $397 billion by 2027. When sourcing potential doctors and nurses for your telemedicine business, pay close attention to the states they are licensed in.To

article thumbnail

NYS DFS Revisits PBM Regulation with Scaled-Back Draft Rules

Health Care Law Brief

On February 6, 2024, the New York State Department of Financial Services (“DFS”) released “pre-proposed” consolidated rulemaking related to the business practices of Pharmacy Benefit Managers (“PBMs”) licensed to operate in New York. The draft regulations contemplate an enforcement date beginning July 1, 2025.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

How AI and Intelligent Automation Can Support and Retain Nurses

HIT Consultant

In fact, about 100,000 registered nurses left the workforce during the past two years due to stress, burnout and retirements, and another 610,388 reported an intent to leave by 2027, according to a study released by the National Council of State Boards of Nursing.

Nurses 103
article thumbnail

Pfizer Acquires Seagen for $43B to Tackle Cancer

HIT Consultant

Clinical development programs are ongoing for each of these medicines for potential new tumor types or expanded indications in earlier lines of therapy, with catalysts expected annually through 2027. Acquisition Impact Seagen expects to generate approximately $2.2

FDA 52
article thumbnail

Understanding the 2025 Medicare Part D Re-design: What You Need to Know

Innovaare Compliance

6] A compound drug not approved by the FDA under a New Drug Application or Biological License Application does not meet the definition of an applicable drug and will not be eligible for Part D. Rebates from the selected drugs may change. Additional drugs will be selected for negotiation every year after 2025. [6] Non-applicable drugs (i.e.,

article thumbnail

February 2022 State Regulatory Developments

New Jersey Healthcare Blog

For 2023 the healthcare cost growth benchmark is 3.5%, for 2024 3.2%, for 2025 3%, for 2026 2.8%, for 2027 2.8%. d), to permit the Committee to count clinical hours obtained before the submission of the proposed plan of supervision toward the number of supervised hours required to become a licensed counselor. See proposed N.J.A.C.

article thumbnail

From Discretion to Regulation: What FDA’s Final Rule Means for Laboratory Developed Tests

Hall Render

Stage 3: Effective May 6, 2027 Three years after the Final Rule’s publication, the FDA will enforce all remaining quality system requirements (under 21 C.F.R. Part 820), providing added oversight over the quality management of LDTs.

FDA 40